Repligen Corporation has acquired 908 Devices' desktop portfolio, which includes four analytical devices for bioprocessing applications, for $70 million in cash. This acquisition enhances Repligen's ...
WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer ...
Portfolio includes PAT devices for real-time process monitoring, control and analysis Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果